Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Increase in Short Interest

Vistagen Therapeutics, Inc. (NASDAQ:VTGNGet Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 658,100 shares, an increase of 46.2% from the December 31st total of 450,000 shares. Approximately 2.6% of the company’s stock are sold short. Based on an average trading volume of 276,000 shares, the days-to-cover ratio is currently 2.4 days.

Institutional Trading of Vistagen Therapeutics

A number of hedge funds have recently modified their holdings of VTGN. Valence8 US LP bought a new position in Vistagen Therapeutics during the 3rd quarter worth $103,000. HighTower Advisors LLC acquired a new stake in shares of Vistagen Therapeutics in the third quarter valued at approximately $64,000. Jane Street Group LLC bought a new stake in shares of Vistagen Therapeutics in the third quarter valued at approximately $59,000. American Century Companies Inc. grew its position in Vistagen Therapeutics by 49.1% during the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock worth $105,000 after buying an additional 9,984 shares in the last quarter. Finally, R Squared Ltd bought a new position in Vistagen Therapeutics during the 4th quarter worth $25,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

Vistagen Therapeutics Price Performance

Shares of NASDAQ VTGN opened at $2.94 on Friday. The stock has a 50 day moving average price of $2.77 and a 200 day moving average price of $3.06. Vistagen Therapeutics has a 52 week low of $2.22 and a 52 week high of $5.74.

Vistagen Therapeutics (NASDAQ:VTGNGet Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.02). Vistagen Therapeutics had a negative net margin of 4,521.71% and a negative return on equity of 36.35%. The firm had revenue of $0.18 million during the quarter, compared to the consensus estimate of $0.34 million. During the same period in the prior year, the business posted ($0.66) earnings per share. As a group, sell-side analysts predict that Vistagen Therapeutics will post -1.85 earnings per share for the current year.

Vistagen Therapeutics Company Profile

(Get Free Report)

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

Recommended Stories

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.